Millennium Management
ENGN icon

Millennium Management’s enGene Therapeutics ENGN Stock Holding History

Millennium Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.54M Sell
959,681
-539,839
-36% -$4.81M ﹤0.01% 2629
2025
Q4 		$13.5M Buy
1,499,520
+1,479,018
+7,214% +$11.9M 0.01% 1949
2025
Q3 		$140K Buy
20,502
+7,472
+57% +$34.1K ﹤0.01% 5636
2025
Q2 		$47.4K Buy
+13,030
New +$48.9K ﹤0.01% 5623

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Millennium Management's ENGN Position: Q1 2026 in Review

Millennium Management reduced its enGene Therapeutics (ENGN) stake by 36% in Q1 2026, selling an estimated $4.81M and leaving 959,681 shares worth $6.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2629.

Millennium Management first reported a position in ENGN in Q2 2025 and has held it in 4 quarters since. The position peaked at $13.5M in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Millennium Management held 959,681 shares of enGene Therapeutics worth $6.54M as of Q1 2026.
  • Millennium Management sold 539,839 enGene Therapeutics shares in Q1 2026, an estimated $4.81M.
  • enGene Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2629 holding.
  • Millennium Management first reported a position in enGene Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Millennium Management's enGene Therapeutics position peaked at $13.5M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.